RESUMO
Objective: To describe the clinical-epidemiological profile of Multisystem Inflammatory Syndrome in Children (MIS-C) cases and to identify factors associated with MIS-C deaths in Brazil, 2020. Methods: Cross-sectional study, based on MIS-C national monitoring database in Brazil, 2020. Simple and multiple logistic regression was performed to estimate crude and adjusted odds ratios (OR). Results: The median age of cases (n=652) was 5 years, 57.1% were male, 52.0% were brown race/color and 6.4% died. The odds of death was greater among those who presented O2 saturation <95% (ORa=4.35 95%CI 1.69;11.20) and altered result of urea (ORa=5.18 95%CI 1.91;14.04); lower in the absence of cutaneous lesion such as rash (ORa=0.23 95%CI 0.09;0.62), with the use of anticoagulants (ORa=0.32 95%CI 0.12;0.89) and of immunoglobulins (ORa=0.38 95%CI 0.15;1.01). Conclusion: Fatality rates was higher among cases that presented O2 saturation<95% and altered urea, and lower among those with cutaneous lesion, who used immunoglobulins and anticoagulants.
Objetivo: Caracterizar o perfil clínico-epidemiológico da síndrome inflamatória multissistêmica pediátrica temporalmente associada à COVID-19 (SIM-P) e identificar fatores associados aos óbitos de SIM-P no Brasil, 2020. Métodos: Estudo seccional, utilizando dados do monitoramento nacional da SIM-P. Empregou-se regressão logística para estimar razões de chances (ORs, odds ratios) brutas e ajustadas. Resultados: Os casos (n=652) apresentaram idade mediana de 5 anos; 57,1% eram do sexo masculino e 52,0% de raça/cor da pele parda; 6,4% evoluíram a óbito. A chance de óbito foi significativamente maior nos que apresentaram saturação de O2<95% (ORa=4,35 IC95% 1,69;11,20) e resultado alterado de ureia (ORa=5,18 IC95% 1,91;14,04); e menor na ausência de manchas vermelhas pelo corpo (ORa=0,23 IC95% 0,09;0,62), com uso de anticoagulantes (ORa=0,32 IC95% 0,12;0,89) e imunoglobulinas (ORa=0,38 IC95% 0,15;1,01). Conclusão: A letalidade foi maior entre casos que apresentaram saturação de O2<95% e ureia alterada; e menor nos que apresentaram manchas vermelhas, usaram imunoglobulinas e anticoagulantes.
RESUMO
A 21-year-old mole was admitted because of fever, fatigue, headache, pharyngitis, abdominal pain, loss of appetite, vomiting and dark urine for three days. The patient denied recent use of medicines or any other drug. His physical examination disclosed jaundice, hepato-splenomegaly, whitish-yellow covered tonsils, bilateral anterior and posterior cervical lymph node enlargement associated with edema on the face and neck. Routine blood tests detected abnormalities in serum bilirubins and liver enzymes (total bilirubin: 14.5 mg/dl, direct-reacting bilirubin: 12.9 mg/dl, AST: 697 U/l, ALT: 619 U/l, alkaline phosphatases: 260 U/l, and GGT: 413 U/l). Serological tests showed negative results for viral hepatitis, cytomegalovirus, HIV-1 and HIV-2, and toxoplasmosis markers, while serology for recent infection by EBV was positive (IgM: 70 and 29 U/ml; EBV IgG: 25 and 156 U/ml). Although infrequently, EBV infection can cause acute hepatitis with accentuated cholestatic jaundice (5% of cases), which may constitute an additional diagnostic challenge for primary care physicians. The patient improved with supportive management and was discharged after 12 days. This case study might contribute to increase the suspicion index about acute hepatitis related to EBV.
Assuntos
Hepatite Viral Humana/etiologia , Mononucleose Infecciosa/diagnóstico , Doença Aguda , Adulto , Hepatite Viral Humana/diagnóstico , Herpesvirus Humano 4/imunologia , Humanos , Mononucleose Infecciosa/complicações , MasculinoRESUMO
A 21-year-old mole was admitted because of fever, fatigue, headache, pharyngitis, abdominal pain, loss of appetite, vomiting and dark urine for three days. The patient denied recent use of medicines or any other drug. His physical examination disclosed jaundice, hepato-splenomegaly, whitish-yellow covered tonsils, bilateral anterior and posterior cervical lymph node enlargement associated with edema on the face and neck. Routine blood tests detected abnormalities in serum bilirubins and liver enzymes (total bilirubin: 14.5 mg/dl, direct-reacting bilirubin: 12.9 mg/dl, AST: 697 U/l, ALT: 619 U/l, alkaline phosphatases: 260 U/l, and GGT: 413 U/l). Serological tests showed negative results for viral hepatitis, cytomegalovirus, HIV-1 and HIV-2, and toxoplasmosis markers, while serology for recent infection by EBV was positive (IgM: 70 and 29 U/ml; EBV IgG: 25 and 156 U/ml). Although infrequently, EBV infection can cause acute hepatitis with accentuated cholestatic jaundice (5% of cases), which may constitute an additional diagnostic challenge for primary care physicians. The patient improved with supportive management and was discharged after 12 days. This case study might contribute to increase the suspicion index about acute hepatitis related to EBV.
Un paciente varón de 21 años, fue hospitalizado por fiebre, astenia, cefalea, faringitis, dolor abdominal, pérdida del apetito, vómitos y orina oscura desde tres días antes. El paciente negó uso reciente de medicamentos y cualquier otra droga. Su examen físico reveló ictericia, hepato-esplenomegalia, amigdalitis, adenopatías cervicales anteriores y posteriores, asociadas con edema facial y cervical. Los exámenes de laboratorio mostraron elevación sérica de bilirrubina y enzimas hepáticas (bilirrubina total: 14,5 mg/dl, bilirrubina directa: 12,9 mg/dl, AST: 697 U/l, ALT: 619 U/l, fosfatasas alcalinas: 260 U/l, y gama-GT: 413 U/l). Los tests serológicos resultaron negativos para hepatitis viral A, B o C, citomegalovirus, VIH-1 y VIH-2, y toxoplasmosis; pero la serología de infección reciente por VEB fue positiva (IgM: 70 y 29 U/ml; IgG: 25 y 156 U/ml). Aunque raramente, las infecciones por VEB pueden causar una hepatitis aguda con acentuada ictericia colestásica (5% de los casos), que suele constituir un desafío diagnóstico adicional para los médicos en atención primaria. El paciente mejoró durante un tratamiento de apoyo y recibió alta hospitalaria después de 12 días. Este caso estimula a aumentar el índice de sospecha de hepatitis aguda relacionada con VEB.
